Last $54.53 USD
Change Today +1.31 / 2.46%
Volume 401.5K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:50 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John M. Maraganore M.D., Ph.D.

Chief Executive Officer and Executive Director, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 182 board members in 8 different organizations across 10 different industries.

See Board Relationships
50$2,416,010
As of Fiscal Year 2012

Background*

Dr. John M. Maraganore, Ph.D. has been the Chief Executive Officer of Alnylam Pharmaceuticals Inc. since December 2002. Dr. Maraganore served as the President of Alnylam Pharmaceuticals Inc. from December 2002 to December 2007. Dr. Maraganore has been a Venture Partner at Third Rock Ventures, LLC since May 14, 2013. He served as Board Advisor at NeuroPhage Pharmaceuticals, Inc. since 2009. From April 2000 to December 2002, he served as Officer, member of the management ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

Director
Director
2002-Present
Chief Executive Officer and Executive Director
2006-2009
Former Director
2006-Present
Director and Member of Compensation Committee
2009-Present
Director and Member of Compensation Committee
2010-N/A
Former Director
2011-Present
Director, Member of Audit Committee and Member of Compensation Committee
2012-Present
Director and Member of Compensation Committee

Education*

MS
The University of Chicago
PhD
The University of Chicago

Other Affiliations*

Annual Compensation*

Salary$669,500
Total Annual Compensation$669,500

Stock Options*

All Other Compensation$8,798
Exercised Options18,617
Exercised Options Value$332,593
Exercisable Options1,324,117
Unexercisable Options363,750
Total Value of Options$332,593
Total Number of Options1,706,484

Total Compensation*

Total Annual Cash Compensation$991,625
Total Short Term Compensation$669,500
Other Long Term Compensation$8,798
Total Calculated Compensation$2,416,010
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $54.53 USD +1.31

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
4.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer and Interim Chief Operating Officer
Enzon Pharmaceuticals Inc.
$226.4K
Mark J. Ahn Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$664.9K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.